Abstract
The strategic interplay of of HIV/AIDS diagnostics and therapeutics is one of
the most complex that the healthcare industry has ever seen. In order to cope
with the challenges and opportunities of HIV/AIDS, companies must think on a
global basis, and in addition to the basic pathology and complications of
HIV/AIDS, there are societal and ethical pressures, geopolitical factors, and
evolving marketplace disruptions.
For the development of a coherent strategy in this therapeutic area, companies
must clearly focus on three primary areas, the first of which is strongly
influenced by the latter two:
- market potential,
- epidemiology (including HIV/AIDS patient trends) and
- the current and emerging technologies in both diagnostics and therapeutics.
This in-depth strategic analysis of the worldwide HIV/AIDS market discusses
the technologies available and emerging and discusses realistic and
theoretical market potential and detailed epidimiological assessments for
various geographic regions (many to the national level), including:
- Sub-Saharan Africa
- North Africa/Middle East
- South/Southeast Asia
- East Asia
- Latin America
- Caribbean
- Eastern Europe/Central Asia
- Western/Central Europe
- North America
- Oceania
The report focuses on the policy aspects of HIV/AIDS, the options presented,
the factors associated with strategic market development of HIV/AIDS
diagnostics and therapeutics, and prospects for the future. The major
strategic market effects of epidemiology, medical technology, and market
potential analyses are discussed in detail. The trends in epidemiology and
social/political attitudes towards HIV/AIDS, as well as their impacts on
developing markets, are selected in conjunction with the growing interest in
HIV/AIDS preventive medicine. These are presented to provide the most
informative picture of potential market advances in this field.
Market analysis for this report is limited in the sense of projections, market
shares, etc. Instead, it considers the various aspects of broad market
development and estimates throughout the world. It looks at regions of the
globe in terms of their existing theoretic and realist market potential. This
is tempered by discussions of where and how these markets may develop and the
factors influencing them. This report does not discuss in detail the
individual products that may be marketed in each of these countries. Some
mention is made of specific product types by way of example, but greater
emphasis is placed on the product classes, in their generic sense, and their
application to HIV/AIDS per se and its complications. The focus of the report
is on the strategic factors associated with existing and future market
potentials to provide pharmaceutical and diagnostics companies wishing to
enter the field with a "field general's" perspective.